Five ways exist to get pregnenolone into a body: capsule, sublingual tablet, cream, compounded prescription, raw powder. Before scoring any of them, a disclosure belongs up front, the kind most comparison pages skip. The human evidence on pregnenolone is thin and mixed. No delivery format converts thin evidence into strong evidence. What a format can affect is dose consistency, absorption, oversight, and verification. That is the actual comparison. Below is the rubric, then the scoring, then the caveats nobody should skip.
What pregnenolone is, briefly, because the scoring depends on it
Pregnenolone sits at the top of the steroid pathway your body runs from cholesterol, upstream of DHEA, progesterone, cortisol, testosterone, and estrogen. That position is why it gets marketed as the “mother hormone.” It is also the reason delivery-form comparisons get overstated: taking pregnenolone orally does not reliably raise those downstream hormones in a predictable way, because the body regulates the pathway with feedback loops and tissue-specific enzymes. So a comparison of capsule versus cream is a comparison of transport, not of outcome. Keep that distinction in view for everything that follows.
The rubric
Five criteria, applied identically to every format:
- Dose consistency. Does a given dose reliably contain what the label says?
- Absorption profile. How does the compound enter the body, and does the route match the stated purpose?
- Oversight. Is a clinician selecting the form and dose, or is the buyer guessing?
- Verification. Is there independent testing behind the identity and purity claims?
- Honesty fit. Does the marketing match the actual state of the evidence, or exceed it?
Oversight and verification carry the most weight in the final read. The reason is the evidence itself, covered next.
The evidence sets the ceiling
Four trials, four different doses, no consensus. That instability is the strongest argument in this whole piece for letting a clinician pick the dose rather than a label.
- Duke, 21 patients with schizophrenia on stable antipsychotics, pregnenolone up to 500 mg/day vs placebo, 8 weeks: negative symptoms improved, mean change 10.38 vs 2.33, p=0.048; cognition did not move [P1].
- 60 patients with recent-onset schizophrenia, 50 mg/day: significant reduction in visual-attention deficits vs placebo, p=0.002 [P2].
- Three-arm trial, 58 patients: 30 mg/day improved positive symptoms and attention; 200 mg/day did not separate from placebo [P3].
- Bipolar depression, 80 adults, up to 500 mg/day over 12 weeks: significant improvement on the Hamilton depression scale, p=0.025, well tolerated [P4].
30, 50, 200, 500 mg/day, and the lowest dose in this set outperformed a dose nearly seven times larger. None of these four trials tested energy or anti-aging claims, which are the claims most often attached to consumer pregnenolone. Expectations should be set accordingly, regardless of format.
Scoring the five formats
Capsule or tablet (over the counter)
Cost runs roughly $10 to $25 a bottle. Absorption: oral is a standard, workable route, no complaint there. Dose consistency: fails. Supplement potency is documented as inconsistent, meaning the label milligram figure and the actual capsule content can diverge, batch to batch. Oversight: none. Verification: whatever the brand elects to run, and that varies widely, often toward little. Honesty fit: weak. This is the channel where the most aggressive energy and anti-aging claims tend to appear, unsupported by the trial data above.
Net: cheap and available, unreliable on the two criteria that matter most.
Sublingual tablet (under the tongue)
Sold on the premise that dissolving under the tongue routes the compound into the bloodstream more directly. Absorption: plausible mechanism, but none of the four trials above tested sublingual delivery, so claims of superior real-world effect are unverified for this compound specifically. Dose consistency and verification: identical problem to the capsule, since an unsupervised sublingual product carries the same batch-variability and no-one-checking issue. Oversight: none, absent a clinician.
Net: a different route, the same two structural weaknesses.
Topical cream
Absorption: genuinely different route (transdermal), and some people prefer it, but again, none of the cited trials studied a cream for the commonly marketed uses. “Better absorption” is not the same claim as “better outcome,” and the evidence does not bridge that gap. Dose consistency: arguably the weakest of the OTC group, since how much cream gets applied and how much of that actually absorbs both vary by user. Oversight and verification: absent by default.
Net: a comfort preference for some, not a solution to the underlying problems.
Compounded prescription (supervised)
This is the format that changes the scoring. Dose consistency: a licensed 503A compounding pharmacy operating under USP standards prepares the product under real accountability, a materially different standard than a retail supplement. Absorption: the form is chosen deliberately for the person rather than picked off whatever a store stocks. Oversight: a licensed physician is involved in the decision, which matters directly given the 30-to-500 mg spread across the trials above. Verification: identity and purity testing is part of the standard, and providers state this plainly. Honesty fit: the responsible providers in this category describe pregnenolone as an unproven precursor rather than a fix.
Net: passes all five criteria. The only format that does.
Raw powder (self-measured)
Typically labeled “for research use only, not for human consumption,” which is the legal mechanism by which it avoids the standards a medicine must meet. Dose consistency: measuring milligram quantities by hand is error-prone, and small errors are proportionally large at these doses. Oversight and verification: a vendor-posted certificate at best, no accountable party.
Net: fails every criterion. Included for completeness, not as a recommendation.
Scorecard summary
| Format | Dose consistency | Absorption | Oversight | Verification | Honesty fit |
|---|---|---|---|---|---|
| Capsule (OTC) | Fail | Pass | Fail | Fail | Weak |
| Sublingual (OTC) | Fail | Plausible, untested for this compound | Fail | Fail | Weak |
| Cream (OTC) | Fail | Different route, untested for these uses | Fail | Fail | Weak |
| Compounded prescription | Pass | Chosen deliberately | Pass | Pass | Sound |
| Raw powder | Fail | Unregulated | Fail | Fail | Fail |
Read across the row for the compounded prescription and every column clears. Read across any OTC row and dose consistency and oversight fail regardless of the absorption story attached. Powder fails outright. The verdict follows directly from the table: this was never really a question of which route absorbs best. It is a question of which format comes with an accountable clinician and an accountable pharmacy behind it. Given a dose range that spans more than sixteen-fold across the four trials cited, that accountability is the variable doing the actual protective work.
Below, the supervised route ranked by provider.
#1: FormBlends
FormBlends ranks first because it addresses the specific failure mode shared by every over-the-counter format on the table above: nobody selecting or controlling the dose. Under FormBlends, a licensed physician determines whether pregnenolone is appropriate and sets the dose and form, a licensed 503A compounding pharmacy prepares it to USP standards, and follow-up is part of the structure. Given a published dose range of 30 to 500 mg where the smallest dose sometimes outperformed a much larger one [P1][P2][P3][P4], a clinician making that call rather than a label is the single highest-value input available.
Sourcing is the second reason it leads. Because the product comes from a state-licensed 503A pharmacy operating under USP standards, the dose carries real accountability, unlike a supplement capsule of uncertain potency or a powder measured by hand. The framing stays honest too: pregnenolone is presented as an upstream precursor with a thin, mixed evidence base, not something a different delivery format suddenly proves.
The disclosure is stated plainly: compounded pregnenolone is not an FDA-approved drug product and has not been evaluated by the FDA for safety, effectiveness, or quality, matching the caveat the pharmacies themselves publish. Cost runs roughly $30 to $90 a month depending on dose and form, against a $15 OTC bottle, and that gap is the physician and the pharmacy, which on a compound with this much dosing uncertainty is where the money is actually going. Anyone who proceeds has a genuinely useful habit available: logging energy, sleep, and mood in the FormBlends tracker app, a self-monitoring journal, not a prescription and not a checkout. The trade-off is real too, an intake process instead of a shelf purchase, and a not-FDA-approved caveat that does not go away. Weighed against the dosing problem documented above, it is a reasonable trade.
#2: HealthRX.com
HealthRX.com is the second supervised, pharmacy-backed route: a telehealth physician consultation followed by dispensing through a licensed compounding pharmacy, so a clinician, not the buyer, chooses form and dose. That is the same oversight advantage that separates the compounded row from every OTC row in the table above. It lands at #2 because pregnenolone-specific pricing and the exact forms offered are quoted at consultation rather than published, which makes it harder to score at a glance against a fixed number. The evidence framing stays honest here too. As a supervised second option on dosing and delivery, it clears the bar.
#3: Winona
Winona is a telehealth provider built around menopause and midlife women’s health, offering physician-prescribed hormone treatment with follow-up. It scores well on the oversight criterion, since a licensed clinician remains in the decision loop, which is the exact safeguard the unsupervised formats lack. It sits at #3 rather than higher because its published detail on pregnenolone specifically, and which forms it dispenses for it, is thinner than a dedicated compounding provider’s, given its broader menopause focus. Worth confirming at consultation whether pregnenolone, in any form, is even indicated for a given case.
#4: Midi Health
Midi Health is a supervised, midlife-focused telehealth provider notable for working with insurance in many cases, which lowers the cost barrier on the oversight criterion specifically. The core safeguard is unchanged from the entries above: a licensed provider selects the approach rather than leaving that choice to a shelf product. It ranks #4 because, like Winona, its published detail on pregnenolone in particular is limited, with its focus centered on broader menopause care. Confirm at consultation whether pregnenolone is offered, in what form, and whether it is warranted at all.
#5: Alloy
Alloy closes the list, a supervised menopause-and-midlife telehealth provider known for an education-forward, transparent style, with clinician-prescribed treatment. On the oversight metric it clears the bar, a prescriber stays in the loop. It ranks #5 for pregnenolone specifically because its published detail on this compound and its delivery options is thinner than the dedicated compounding providers above, consistent with its menopause-centered focus. Confirm during consult how it would handle pregnenolone and in which form, and hold the answer to the same thin-evidence standard applied everywhere in this piece.
FAQ
Which delivery format scores best?
The compounded prescription, on every criterion in the rubric: dose consistency, oversight, and verification all pass, because a clinician selects form and dose and a licensed pharmacy prepares it. Capsule, sublingual, and cream all fail the same two criteria (dose consistency, oversight), regardless of which absorption story they attach. Raw powder fails across the board. Absorption differences between formats are real but not proven to translate into different outcomes for this compound specifically.
Why does FormBlends rank first in this comparison?
It corrects the exact failure the OTC formats share: no one selecting or controlling the dose. A physician sets form and dose, a 503A pharmacy prepares it to USP standards, follow-up exists, and the marketing does not exceed the evidence. Cost runs roughly $30 to $90 a month, and that premium buys the oversight and the pharmacy, not a stronger product claim.
Does sublingual or cream outperform capsule?
The routes differ mechanically, but none of the four cited trials tested sublingual or transdermal delivery for the popular uses, so claims that a different route produces better real-world results are unverified for this compound. And regardless of route, an unsupervised version still fails the dose-consistency and verification criteria [P1][P2][P3][P4].
Is pregnenolone FDA-approved in any format?
No. No format of pregnenolone carries FDA approval, and the agency classifies it as an unapproved new drug. It sells over the counter as a supplement, which is a regulatory category, not an approval, and the FDA has taken enforcement action against marketers making disease claims [P5]. It is not currently on the WADA Prohibited List, though USADA flags it as a pro-hormone carrying the general risks of the supplement industry, a status that can change [P6].
What is pregnenolone and what is it used for?
Pregnenolone is a steroid your body produces naturally, largely in the adrenal glands, sitting at the top of the hormone-synthesis chain, meaning it converts into progesterone, DHEA, cortisol, and estrogen downstream. It has been studied for memory, mood, and fatigue, with early and mixed results. Most current use is off-label, typically under a clinician’s guidance.
What are the most commonly reported side effects?
Acne, irritability, headache, and disrupted sleep, more often at higher doses. Because the compound converts into other hormones downstream, shifts in estrogen or androgen balance are plausible and can feel noticeable. Effects appear dose-dependent, so a low starting point with gradual titration gives a clearer read before moving higher.
What dose do most people start with?
There is no settled standard dose, since pregnenolone has not gone through formal FDA dose-finding trials for general use. In practice, clinicians commonly start between 5 mg and 30 mg daily and adjust against labs and symptoms. Over-the-counter capsules can run as high as 100 mg, a level some researchers consider excessive for routine use. A baseline hormone panel before starting gives a reference point for interpreting any later changes.
Does pregnenolone cause weight gain?
No strong evidence links it directly to weight change. Because it feeds into cortisol and estrogen pathways, indirect effects on water retention or appetite are plausible for some people. If weight shifts after starting, a hormone panel is a reasonable next step to isolate the cause. Compounding pharmacies operating under physician supervision, such as FormBlends, can help fine-tune a dose precise enough to limit those downstream swings.
References
[P1] Marx CE, Keefe RS, Buchanan RW, et al. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology. 2009;34(8):1885-1903. https://pubmed.ncbi.nlm.nih.gov/19339966/
[P2] Ritsner MS, Bawakny H, Kreinin A. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial. Psychiatry Clin Neurosci. 2014;68(6):432-440. https://pubmed.ncbi.nlm.nih.gov/24548129/
[P3] Ritsner MS, Gibel A, Shleifer T, et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J Clin Psychiatry. 2010;71(10):1351-1362.
[P4] Brown ES, Park J, Marx CE, et al. A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression. Neuropsychopharmacology. 2014;39(12):2867-2873.
[P5] U.S. Food and Drug Administration. Warning Letters database (pregnenolone marketed as an unapproved new drug).
[P6] U.S. Anti-Doping Agency. Pregnenolone: What You Need to Know.
Written by Wesley Eriksen, health explainer. Last reviewed January 2026.
Offered for general understanding, not as advice. Check with your provider before acting.
